Follow us on:

N4 Pharma MTAs demonstrate commercial interest (Analyst Interview)

Giles
July 19, 2021
10:41 am

N4 Pharma plc (LON:N4P) is the topic of conversation when SP Angel Analyst Vadim Alexandre joins DirectorsTalk. Vadim talks us through the main points of their latest research note, explains what the current vaccine landscape means for the company, why someone might want to invest in the company and what can be expected from N4 over the coming months.

N4 Pharma, are a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines.

Find more news, interviews, share price & company profile here for:

Share this interview

Other Interviews

More News

N4 Pharma broker offer to raise a maximum of £1 million November 18, 2022
N4 Pharma updates on patent filing November 1, 2022
N4 Pharma successful Nuvec double siRNA testing October 4, 2022
N4 Pharma plans for commercialising Nuvec (VIDEO) September 15, 2022
N4 Pharma identifies a very strong commercial point of difference for Nuvec September 14, 2022
N4 Pharma announce a further update on its study with TNF alpha July 15, 2022
N4 Pharma’s proof of concept work is extremely encouraging June 13, 2022
N4 Pharma AGM to be held on 24 March 2022 February 24, 2022
N4 Pharma successful work in formulating Nuvec as a monodispersed formulation January 25, 2022
Very promising results from N4 Pharma’s oncology study January 4, 2022

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.